Economic burden of rotavirus diarrhea in Thailand: Report from a pilot study on rotavirus vaccination

Rochanathimoke, Onwipa; Riewpaiboon, Arthorn; Tharmaphornpilas, Piyanit; Jiamsiri, Suchada; Thavorncharoensap, Montarat; Postma, Maarten J.

doi:10.1016/j.vaccine.2018.12.013

Cited by 8 publications

(4 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Numerous studies have reported the economic burden of childhood diarrhea in different settings; however, empirical data on the cost of diarrheal illness is sparse [25][26][27][28][29]. We found that the average cost of AD per episode in children under five years of age in Ecuador was US $45.24 (2019 dollars).…”

Section: Plos Onementioning

confidence: 78%

Medical cost of acute diarrhea in children in ambulatory care

Choez

Leal²,

Padilla³

et al. 2022

PLoS ONE

View full text Add to dashboard Cite

Objective The aim of this study was to estimate the direct medical cost per episode and the annual cost for acute diarrhea (AD) in children under five years of age in Ambulatory Care Centers of the Ministry of Public Health (MOPH) of Ecuador. Methods A cost of illness study with a provider perspective was carried out through a micro-costing of health resources and valuated in international dollars. Medical consultations and laboratory tests were valued using the tariff framework of services for the National Health System and for the prescribed medications, a reported cost registry of pharmacy purchases made in the year of study was used. Results A total of 332 electronic health records of children under five years of age were included in the analysis. Laboratory tests were performed on 37.95% (126/332), medications were prescribed to 93.67% (311/332) of the children, and antimicrobials were prescribed to 37.35% (124/332) of the children, representing an antibiotic prescription rate of 26.51% (88/332) and an antiparasitic prescription rate of 10.84% (36/332). The mean cost of the MOPH per child per episode of AD was US$45.24 (2019 dollars) (95% CI:43.71 to 46.76). Conclusion The total estimated cost of AD in children under five years of age for the MOPH in 2019 was about US$6,645,167.88 million (2019 dollars) (95% CI: 6,420,430.77 to 6,868,436.12). A high proportion of the direct medical cost of AD in children under five years of age in outpatient settings is due to unnecessary laboratory tests.

show abstract

Section: Plos Onementioning

confidence: 78%

Medical cost of acute diarrhea in children in ambulatory care

Choez

Leal²,

Padilla³

et al. 2022

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…Direct medical and non-medical costs included costs of hospitalization, ambulatory care and self-care. The data were based on the pilot project [7] and were published elsewhere [24]. The treatment costs (e.g.…”

Section: Cost Datamentioning

confidence: 99%

Economic evaluation of rotavirus vaccination: an important step of the introduction to the national immunization program in Thailand

Rochanathimoke

Riewpaiboon

Praditsitthikorn

et al. 2021

Expert Review of Pharmacoeconomics & Outcomes Research

Self Cite

View full text Add to dashboard Cite

Introduction: World Health Organization recommends rotavirus vaccine for all national immunization programs (NIPs). To provide country-specific evidence, we conducted economic evaluation of a monovalent rotavirus vaccination using specific data of the pilot phase in Thailand. Method: A Markov model was adopted to compare the 2020 birth cohort once receiving rotavirus vaccination versus no vaccination from healthcare and societal perspective over five years. Data on disease burden, vaccine effectiveness, costs, and utilities were taken from a cohort study in two provinces of Thailand. Sensitivity analyses were performed to test the robustness of the results. Results: Rotavirus vaccination would reduce rotavirus diarrhea and costs of illness by 48% and 71%, respectively, over the first five years of life. At USD 13 per dose, vaccine was cost-effective with the ICERs of USD 4,114 and USD 1,571per QALY gained from healthcare and societal perspective, respectively. Results were sensitive to incidence and vaccine cost. The budget for vaccine purchasing was estimated at USD13 million per year. Conclusion:Incorporating rotavirus vaccination into the NIP substantially reduced health and cost outcomes and was cost-effective for both perspectives. However, the government needs to negotiate vaccine price prior to program implementation to achieve favorable budget impact.

show abstract

“…Particularly, we found two studies assessing the cost of measles in the Federated States of Micronesia [49] and the cost of measles and rubella in Romania [50] -a first for measles and rubella in LMIC. Other studies examined further the cost of GE [51][52][53][54][55][56][57][58][59], pneumonia [51,52,[59][60][61][62][63], and influenza [64,65]. Some of them generated COI estimates from a programmatic approach, evaluating the cost of treating diarrhea and pneumonia through an integrated community case management [51,52,59].…”

Section: Limitations Of This Systematic Reviewmentioning

confidence: 99%

Cost of Nine Pediatric Infectious Illnesses in Low- and Middle-Income Countries: A Systematic Review of Cost-of-Illness Studies

Broucker¹,

Sim

Brenzel

et al. 2020

PharmacoEconomics

View full text Add to dashboard Cite

Background Cost-of-illness data from empirical studies provide insights into the use of healthcare resources including both expenditures and the opportunity cost related to receiving treatment. Objective The objective of this systematic review was to gather cost data and relevant parameters for hepatitis B, pneumonia, meningitis, encephalitis caused by Japanese encephalitis, rubella, yellow fever, measles, influenza, and acute gastroenteritis in children in low- and middle-income countries. Data Sources Peer-reviewed studies published in public health, medical, and economic journals indexed in PubMed (MEDLINE), Embase, and EconLit. Study Eligibility Criteria, Participants, and Interventions Studies must (1) be peer reviewed, (2) be published in 2000–2016, (3) provide cost data for one of the nine diseases in children aged under 5 years in low- and middle-income countries, and (4) generated from primary data collection. Limitations We cannot exclude missing a few articles in our review. Measures were taken to reduce this risk. Several articles published since 2016 are omitted from the systematic review results, these articles are included in the discussion. Conclusions and Implications of Key Findings The review yielded 37 articles and 267 sets of cost estimates. We found no cost-of-illness studies with cost estimates for hepatitis B, measles, rubella, or yellow fever from primary data. Most estimates were from countries in Gavi preparatory (28%) and accelerated (28%) transition, followed by those who are initiating self-financing (22%) and those not eligible for Gavi support (19%). Thirteen articles compared household expenses to manage illnesses with income and two articles with other household expenses, such as food, clothing, and rent. An episode of illness represented 1–75% of the household’s monthly income or 10–83% of its monthly expenses. Articles that presented both household and government perspectives showed that most often governments incurred greater costs than households, including non-medical and indirect costs, across countries of all income statuses, with a few notable exceptions. Although limited for low- and middle-income country settings, cost estimates generated from primary data collection provided a ‘real-world’ estimate of the economic burden of vaccine-preventable diseases. Additional information on whether common situations preventing the application of official clinical guidelines (such as medication stock-outs) occurred would help reveal deficiencies in the health system. Improving the availability of cost-of-illness evidence can inform the public policy agenda about healthcare priorities and can help to operationalize the healthcare budget in local health systems to respond adequately to the burden of illness in the community.

show abstract

Economic burden of rotavirus diarrhea in Thailand: Report from a pilot study on rotavirus vaccination

Cited by 8 publications

References 32 publications

Medical cost of acute diarrhea in children in ambulatory care

Medical cost of acute diarrhea in children in ambulatory care

Economic evaluation of rotavirus vaccination: an important step of the introduction to the national immunization program in Thailand

Cost of Nine Pediatric Infectious Illnesses in Low- and Middle-Income Countries: A Systematic Review of Cost-of-Illness Studies

Contact Info

Product

Resources

About